Figure 5. JO-1 improves trastuzumab therapy in Her2/neu positive breast cancer models.
A) BT474-M1 breast cancer model: When tumors reached a volume of ~100 mm3, mice received an intravenous injection of JO-1 or PBS, followed by an intraperitoneal injection of trastuzumab or PBS 10 h later. A second treatment cycle was started at day 36 (marked by arrows). Shown is the increase in tumor volume (compared to pretreatment levels at day 29). n=5. * p<0.05. B) HCC1954 breast cancer model: Mice were treated as in A). Mice received the first treatment at day 12. Treatment was repeated at day 18. n = 5. * p<0.05. C) Mice bearing HCC1954 breast cancer tumors were injected with a mixture of JO-1 and trastuzumab, JO-1 followed by trastuzumab 1 h later and, JO-1 followed by trastuzumab 10 h later. Injections were repeated weekly. n=5. All JO-1 cotherapies are significantly more effective than trastuzumab alone. There is not significant difference between the different cotherapy regimens.